RNAC
Cartesian TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade C from latest DB weights. Momentum 55.9 / Value 41.1
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.3.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
56
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $35.57
Why
Momentum56 · Δ7d -0.3
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
56
52% active weight
Current posture
7d trendSoftening
Δ7d
-0.3
Δ21d
-22.5
Value
41
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 55.9 / Value 41.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$203.32M
Beta
0.45
Shares Out
26M
P/E (TTM) · Derived
-1.7
P/S (TTM)
93.25
P/FCF (TTM) · Derived
-2.94
Rev YoY
+16.8%
EPS YoY
-22.6%
Gross Margin
-
Op Margin
-4748.2%
Net Debt
-$212.61M
Current Ratio
10.67
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology